Oncology Updates Archives - Page 2 of 4 - Cadence

Market Access Market Research Oncology Updates

Take a Look Into Our Market Access Work

Market Access Market Research Oncology Updates

Are you getting the most out of the Specialty Pharmacies (SPs) in your network / HUB?

Approval Blog Medical Communications Oncology Updates

Dabrafenib and Trametinib for the Treatment of BRAF V600E-positive Anaplastic Thyroid Cancer

Approval Blog Medical Communications Oncology Updates

Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma

Approval Blog Medical Communications Oncology Updates

Dabrafenib and Trametinib for Adjuvant Treatment of BRAF V600E/K-Positive Melanoma

Oncology Updates

Leveraging Innovation Centers to Re-prime the Development Pump!

Approval Blog Medical Communications Oncology Updates

Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC

Approval Blog Medical Communications Oncology Updates

Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma

Approval Blog Medical Communications Oncology Updates

Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Approval Blog Medical Communications Oncology Updates

Blinatumomab for Patients with MRD-positive B-cell Precursor ALL